Tanvex Biopharma (TANVF) Financial Statements
Tanvex Biopharma Financial Overview
Tanvex Biopharma's market cap is currently $231.44M. The company's EPS TTM is ―; its P/E ratio is ―; Tanvex Biopharma has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | ― | ― | ― | ― | ― |
| Gross Profit | $ -19.35M | $ 3.55M | $ 143.00K | $ 0.00 | $ 0.00 |
| Operating Income | $ -1.61B | $ -1.60B | $ -2.10B | $ -2.33B | $ -1.95B |
| EBITDA | $ -1.30B | $ -1.25B | $ -1.87B | $ -2.04B | $ -1.75B |
| Net Income | $ -1.64B | $ -1.54B | $ -2.10B | $ -2.27B | $ -1.89B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | ― | ― | ― | ― | ― |
| Total Assets | $ 3.42B | $ 4.71B | $ 4.37B | $ 3.57B | $ 4.48B |
| Total Debt | $ 1.84B | $ 1.76B | $ 1.46B | $ 342.74M | $ 0.00 |
| Net Debt | $ 1.05B | $ -463.95M | $ -603.96M | $ -2.08B | $ -3.53B |
| Total Liabilities | $ 2.03B | $ 1.92B | $ 1.75B | $ 542.12M | $ 263.92M |
| Stockholders' Equity | ― | ― | ― | ― | ― |
| Cash Flow | |||||
| Free Cash Flow | $ -1.43B | $ -1.42B | $ -1.86B | $ -1.99B | $ -1.71B |
| Operating Cash Flow | ― | ― | ― | ― | ― |
| Investing Cash Flow | ― | ― | ― | ― | ― |
| Financing Cash Flow | ― | ― | ― | ― | ― |
Currency in USD
